

REMARKS/ARGUMENTS

Claim status. Claims 2 to 5, 7 to 13 and 25 to 27 are pending in this application. Claim 10 to 13 and 25 are amended hereby. Claims 26 and 27 have been added.

Claim 26 is intended to correspond to the subject matter deemed allowable by the Examiner (page 9 of the Office Action of January 13, 2004). The Applicants still wish to pursue the remaining claims and respectfully request consideration thereof.

Support for amendments. No new matter is added by the current amendments to the specification and claims.

The new Sequence Listing merely corrects errors in the previous Sequence Listing. The Examiner noted that the Sequence Listing included only 135 sequences but that Claim 25 recited up to SEQ ID NO: 137. All of the sequences currently in the Sequence Listing are in the specification as previously filed, so no new matter is added by the amendment to the Sequence Listing or the corresponding amendments to the specification. A substitute Sequence Listing is submitted herewith.

Among other portions of the specification providing support, the amended claims are supported in the specification as follows. Claim 10 is supported at page 17, lines 9 to 12; Claim 11, at pages 18 to 21; Claim 12, at page 21, table 6; and Claims 13, 26, and 27, at page 42, line 26 to page 43, line 6.

Objection under Section 132. The Applicants repeat their remarks in the Amendment of June 14, 2004.

Rejection of Claims. The Applicants repeat their remarks in the Amendment of June 14, 2004 and respectfully request guidance explaining the reasons for rejection of the claims as amended.

Appl. No. 09/840,277
Amdt. dated September 8, 2004
Reply to Office Action of June 14, 2004

Conclusion. In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, withdrawal of all objections and rejections, and allowance of all claims.

Respectfully submitted,



Timothy J. Gault

Attorney for Applicant

Registration No.: 33,111

Phone: (805) 447-2688

Date: September 8, 2004

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799